Perseus Proteomics, Inc. (JP:4882) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perseus Proteomics Inc. has announced the extension of its phase I/II clinical trial for its drug PPMX-T003, targeting the rare aggressive NK-cell leukemia, until March 2026 due to challenges in subject registration. The company is analyzing the potential impact of this extension on its financial results for the current and following fiscal years.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.